155 related articles for article (PubMed ID: 9554278)
21. Inactivated virosome hepatitis A vaccine.
Loutan L; Bovier P; Althaus B; Glück R
Lancet; 1994 Feb; 343(8893):322-4. PubMed ID: 7905144
[TBL] [Abstract][Full Text] [Related]
22. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
[TBL] [Abstract][Full Text] [Related]
23. Development of novel fusogenic vesosomes for transcutaneous immunization.
Mishra V; Mahor S; Rawat A; Dubey P; Gupta PN; Singh P; Vyas SP
Vaccine; 2006 Jul; 24(27-28):5559-70. PubMed ID: 16730102
[TBL] [Abstract][Full Text] [Related]
24. [Immunogenicity and stability of an aluminum-free liposomal hepatitis A vaccine (Epaxal Berna)].
Wegmann A; Zellmeyer M; Glück R; Finkel B; Flückiger A; Berger R; Just M
Schweiz Med Wochenschr; 1994 Nov; 124(45):2053-6. PubMed ID: 7973542
[TBL] [Abstract][Full Text] [Related]
25. Transcutaneous immunization using a dissolving microneedle array protects against tetanus, diphtheria, malaria, and influenza.
Matsuo K; Hirobe S; Yokota Y; Ayabe Y; Seto M; Quan YS; Kamiyama F; Tougan T; Horii T; Mukai Y; Okada N; Nakagawa S
J Control Release; 2012 Jun; 160(3):495-501. PubMed ID: 22516091
[TBL] [Abstract][Full Text] [Related]
26. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
27. Immunization of healthy adults.
Lawson M
Kans Med; 1994 Oct; 95(10):228-9. PubMed ID: 7815776
[No Abstract] [Full Text] [Related]
28. Clinical experience with inactivated, virosomal influenza vaccine.
de Bruijn IA; Nauta J; Cramer WC; Gerez L; Palache AM
Vaccine; 2005 Jul; 23 Suppl 1():S39-49. PubMed ID: 16005120
[TBL] [Abstract][Full Text] [Related]
29. Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity.
de Vries JJ; Bungener L; Ter Veer W; van Alphen L; van der Ley P; Wilschut J; Huckriede A
Vaccine; 2009 Feb; 27(6):947-55. PubMed ID: 19059296
[TBL] [Abstract][Full Text] [Related]
30. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants.
Zepp F; Knuf M; Heininger U; Jahn K; Collard A; Habermehl P; Schuerman L; Sänger R
Vaccine; 2004 Jun; 22(17-18):2226-33. PubMed ID: 15149781
[TBL] [Abstract][Full Text] [Related]
31. A TritonX-100-split virion influenza vaccine is safe and fulfills the committee for proprietary medicinal products (CPMP) recommendations for the European Community for Immunogenicity, in Children, Adults and the Elderly.
Lina B; Fletcher MA; Valette M; Saliou P; Aymard M
Biologicals; 2000 Jun; 28(2):95-103. PubMed ID: 10885616
[TBL] [Abstract][Full Text] [Related]
32. [Which vaccines for which travelers?].
Louis FJ; Morillon M; Martet G
Med Trop (Mars); 1997; 57(1):27-30. PubMed ID: 9289603
[No Abstract] [Full Text] [Related]
33. Development and evaluation of chitosan microspheres for tetanus, diphtheria and divalent vaccines: a comparative study of subcutaneous and intranasal administration in mice.
Hashem FM; Fahmy SA; El-Sayed AM; Al-Sawahli MM
Pharm Dev Technol; 2013; 18(5):1175-85. PubMed ID: 21985525
[TBL] [Abstract][Full Text] [Related]
34. Influenza virosomes in vaccine development.
Huckriede A; Bungener L; Daemen T; Wilschut J
Methods Enzymol; 2003; 373():74-91. PubMed ID: 14714397
[TBL] [Abstract][Full Text] [Related]
35. [The potentials for immunization against influenza using liposome-incorporated viral surface antigens].
Burducea O; Marcheş F; Duţu C; Grancea C; Nicolau A; Păun C
Virologie; 1989; 40(2):97-106. PubMed ID: 2781727
[TBL] [Abstract][Full Text] [Related]
36. Simultaneous administration of HB recombinant vaccine with diphtheria and tetanus toxoid and oral polio vaccine: a pilot study.
Barone P; Mauro L; Leonardi S; Ienna M; Giammanco Bilancia G; Falcidia E; Musumeci S
Acta Paediatr Jpn; 1991 Aug; 33(4):455-8. PubMed ID: 1838852
[TBL] [Abstract][Full Text] [Related]
37. Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine.
Lambkin R; Oxford JS; Bossuyt S; Mann A; Metcalfe IC; Herzog C; Viret JF; Glück R
Vaccine; 2004 Oct; 22(31-32):4390-6. PubMed ID: 15474733
[TBL] [Abstract][Full Text] [Related]
38. Negatively charged liposomes as immunological adjuvant for tetanus and diphtheria toxoids.
Popescu C; Durbaca S; Ivanov D
Roum Arch Microbiol Immunol; 1998; 57(3-4):255-61. PubMed ID: 11845437
[TBL] [Abstract][Full Text] [Related]
39. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model.
Amidi M; Romeijn SG; Verhoef JC; Junginger HE; Bungener L; Huckriede A; Crommelin DJ; Jiskoot W
Vaccine; 2007 Jan; 25(1):144-53. PubMed ID: 16973248
[TBL] [Abstract][Full Text] [Related]
40. Influenza, pneumonia, tetanus: how effective is vaccination?
Powers DC; Sears SD
Geriatrics; 1987 Oct; 42(10):81-2, 87-90. PubMed ID: 3653696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
